度普利尤单抗治疗儿童特应性皮炎的研究进展

doi:10.35541/cjd.20210730

中华皮肤科杂志 ›› 2023, e20210730.doi: 10.35541/cjd.20210730

度普利尤单抗治疗儿童特应性皮炎的研究进展

田晶梁源马琳

国家儿童医学中心首都医科大学附属北京儿童医院皮肤科，北京 100045

收稿日期:2021-10-08 修回日期:2022-02-07 发布日期:2023-03-01
通讯作者: 马琳 E-mail:bch_maleen@aliyun.com
基金资助:
国家自然科学基金（81673042）；北京市儿科学科协同发展中心“儿科专项”（XTZD20180502）

Dupilumab in the treatment of childhood atopic dermatitis

Tian Jing, Liang Yuan, Ma Lin

Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, China, Beijing 100045, China

Received:2021-10-08 Revised:2022-02-07 Published:2023-03-01
Contact: Ma Lin E-mail:bch_maleen@aliyun.com
Supported by:
National Natural Science Foundation of China （81673042）; The Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals（XTZD20180502）

摘要/Abstract

摘要： 【摘要】目前一般规律使用保湿剂联合外用糖皮质激素/钙调磷酸酶抑制剂治疗儿童特应性皮炎（AD），部分中重度难治性患儿，需系统用糖皮质激素或超说明书使用其他免疫调节剂，然而这些治疗存在一定的局限性及不良反应。近年来，随着AD关键炎症因子的发现，针对白细胞介素4/13的生物制剂——度普利尤单抗广泛应用于临床并取得一定的效果。本文综述近年来度普利尤单抗治疗儿童AD的临床研究。

关键词: 皮炎, 特应性, 儿童, 治疗, 生物制剂, 度普利尤单抗

Abstract: 【Abstract】 Currently, childhood atopic dermatitis （AD） is mainly treated by regular use of moisturisers in combination with topical glucocorticoids or calcineurin inhibitors. For some children with refractory moderate-to-severe AD, systemic glucocorticoids or off-label use of other immunomodulators may be required; however, these treatments usually have some limitations and adverse effects. In recent years, with the discovery of key inflammatory factors in AD, dupilumab, a biological agent targeting interleukin-4/13, has been widely used in clinical practice, and shown certain efficacy. This review summarizes recent clinical studies on dupilumab in the treatment of AD in children.

Key words: Dermatitis, atopic, Child, Therapy, Biological agents, Dupilumab

田晶梁源马琳. 度普利尤单抗治疗儿童特应性皮炎的研究进展[J]. 中华皮肤科杂志, 2023,e20210730. doi:10.35541/cjd.20210730

Tian Jing, Liang Yuan, Ma Lin. Dupilumab in the treatment of childhood atopic dermatitis[J]. Chinese Journal of Dermatology,2023,e20210730. doi:10.35541/cjd.20210730

参考文献 10

［1］	中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识（2017版）［J］. 中华皮肤科杂志, 2017,50（11）:784⁃789. doi: 10.3760/cma.j.issn.0412⁃4030.2017.11.002.
［2］	周杰, 宋志强. 特应性皮炎的临床表型和内表型［J］. 中华皮肤科杂志, 2021,54（3）:259⁃263. doi: 10.35541/cjd.20190741.
［3］	Cork MJ, Thaçi D, Eichenfield L, et al. Dupilumab in adolescents with uncontrolled moderate⁃to⁃severe atopic dermatitis: results from a phase Ⅱa open⁃label trial and subsequent phase Ⅲ open⁃ label extension［J］. Br J Dermatol, 2020,182（1）:85⁃96. doi: 10. 1111/bjd.18476. Epub 2019 Oct 8.
［4］	Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long⁃term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open⁃label phase Ⅱa study and subsequent phase Ⅲ open⁃label extension study［J］. Br J Dermatol, 2021,184（5）:857⁃870. doi: 10.1111/bjd.19460.
［5］	Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open⁃label study of single⁃dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:464⁃475. doi: 10.1111/jdv.16928.
［6］	Siegfried EC, Bieber T, Simpson EL, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo⁃controlled, phase 3 clinical trial［J］. Am J Clin Dermatol, 2021,22（2）:243⁃255. doi: 10.1007/ s40257⁃020⁃00583⁃3.
［7］	Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double⁃blinded, placebo⁃ controlled phase 3 trial［J］. J Am Acad Dermatol, 2020,83（5）:1282⁃1283. doi: https:// doi.org/10.1016/j.jaad.2020.06.054.
［8］	Igelman S, Kurta AO, Sheikh U, et al. Off⁃label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review［J］. J Am Acad Dermatology,2020,82（2）:407⁃411. doi: https://doi.org/10.1016/j.jaad.2019.10. 010.
［9］	Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine⁃induced immunity: a randomized, placebo⁃controlled trial in adults with moderate⁃to⁃severe atopic dermatitis. J Am Acad Dermatol, 2019,80（1）:158⁃167.e1. doi: 10.1016/j.jaad.2018.07.048.
［10］	Martinez⁃Cabriales SA, Kirchhof MG, Constantinescu CM, et al. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020［J］. Am J Clin Dermatol, 2021,22（4）:443⁃455. doi: 10.1007/s40257⁃021⁃00607⁃6.

[1]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[2]	侯晓媛吴南辉徐明圆刘业强. JAK抑制剂巴瑞替尼治疗环状肉芽肿1例[J]. 中华皮肤科杂志, 2024, 57(5): 461-462.
[3]	张玉丽季双双石秀艳孟宪敏刘文慧王冲. 儿童面部获得性色素沉着斑7例[J]. 中华皮肤科杂志, 2024, 57(5): 458-460.
[4]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[5]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[6]	中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 387-399.
[7]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[8]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[9]	中国中西医结合学会皮肤性病学分会真菌学组中国耐药皮肤癣菌病诊治与防控工作组. 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425.
[10]	郭澜晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478.
[11]	刘祎曲莹雷文知刘晓刚潘炜华张超. 食盐封包法治疗化脓性肉芽肿25例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20230553-e20230553.
[12]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[13]	张迪敏曹成周妙妮盛安琪林福全许爱娥. 复方倍他米松注射液联合治疗后进展期非节段型白癜风稳定率及影响因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 350-354.
[14]	周甜甜吴雪歌杨欢方晓蒋金秋陈静思罗晓燕王华. 儿童慢性自发性荨麻疹病因及严重程度相关因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 324-330.
[15]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.

度普利尤单抗治疗儿童特应性皮炎的研究进展

Dupilumab in the treatment of childhood atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 10

相关文章 15

Metrics

本文评价

推荐阅读 10